![Naheed Ismaili Misfeldt](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Naheed Ismaili Misfeldt
Direktor/Vorstandsmitglied bei Visionary Therapeutics Corp.
Ursprung des Netzwerks ersten Grades von Naheed Ismaili Misfeldt
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Visionary Therapeutics Corp.
![]() Visionary Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Visionary Therapeutics Corp. develops ocular therapeutics for eye diseases. The company was founded by Steve Hutcherson and is headquartered in Richmond, VA
2
| Private Company | Pharmaceuticals: Major | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Naheed Ismaili Misfeldt
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
HealthCare Ventures LLC
![]() HealthCare Ventures LLC Investment ManagersFinance HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Fredonia College Foundation
![]() Fredonia College Foundation Miscellaneous Commercial ServicesCommercial Services The Fredonia College Foundation is a non-profit organization that supports the State University of New York at Fredonia by providing financial assistance to students, faculty, and staff. The foundation is based in Fredonia, NY. The foundation offers scholarships, grants, and other forms of aid to help students achieve their academic goals. It also supports research and other initiatives that enhance the educational experience at the university. | Miscellaneous Commercial Services | Director/Board Member | |
Dynacure SA
![]() Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Medical/Nursing Services | Director/Board Member | |
Aro Biotherapeutics Co.
![]() Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member | |
Healthcare Strategic Partners, LLC
![]() Healthcare Strategic Partners, LLC Medical/Nursing ServicesHealth Services Part of HealthCare Ventures LLC, Healthcare Strategic Partners, LLC is an American company that provides healthcare services. | Medical/Nursing Services | Corporate Officer/Principal | |
Healthcare Partners IX LLC | Corporate Officer/Principal | ||
Guilford College | College/University | Director/Board Member | |
LEAP THERAPEUTICS, INC. | Biotechnology | Chairman | |
Healthcare Partners VIII LLC | Corporate Officer/Principal | ||
Galleon Pharmaceuticals, Inc.
![]() Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | Pharmaceuticals: Major | Director/Board Member | |
Anchor Therapeutics, Inc.
![]() Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
FoldRx Pharmaceuticals LLC
![]() FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
TREVENA, INC. | Pharmaceuticals: Major | Director/Board Member | |
The State University of New York College at Fredonia | College/University | Undergraduate Degree | |
IONIS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder | |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Adheron Therapeutics, Inc.
![]() Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Biotechnology | President | |
Theraclone Sciences, Inc.
![]() Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Miscellaneous Commercial Services | Director/Board Member | |
Baylor College of Medicine | College/University | Doctorate Degree | |
SmithKline & French SpA
![]() SmithKline & French SpA Pharmaceuticals: MajorHealth Technology Part of Procter & Gamble Co., SmithKline & French SpA is a pharmaceutical concern. SmithKline & French was acquired by Procter & Gamble Co. from Smithkline Beecham Plc on September 29, 1993. | Pharmaceuticals: Major | Corporate Officer/Principal | |
LeukoSite, Inc.
![]() LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
Flamingo Therapeutics BV
![]() Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Miscellaneous Commercial Services | Chairman |
Statistik
International
Vereinigte Staaten | 26 |
Frankreich | 2 |
Italien | 2 |
Belgien | 2 |
Sektoral
Health Technology | 18 |
Commercial Services | 4 |
Consumer Services | 4 |
Health Services | 3 |
Finance | 2 |
Operativ
Director/Board Member | 18 |
President | 6 |
Chairman | 5 |
Corporate Officer/Principal | 4 |
Chief Executive Officer | 4 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Chris Mirabelli | 29 |
Steve Hutcherson | 1 |
- Börse
- Insiders
- Naheed Ismaili Misfeldt
- Unternehmensverbindungen